Global pharmaceutical leader AstraZeneca is doubling down on its Chinese partnerships, announcing plans to launch over 100 new medicines in the Chinese mainland through its Shanghai innovation hub. Executive VP Sharon Barr revealed the ambitious roadmap in an exclusive CGTN interview, calling it a “win-win collaboration” for global health advancements.
🔬 The Shanghai R&D center – already a hotspot for AI-driven drug discovery – will spearhead efforts to develop treatments for chronic diseases and cancers prevalent in Asia. “Our work here directly addresses regional health needs while contributing to global medical knowledge,” Barr explained.
💡 This move comes as China accelerates its biopharma sector growth, with AstraZeneca positioning itself as a key player in:
Next-gen cancer therapies
Precision medicine platforms
Digital health integration
🌱 Barr emphasized sustainable partnerships: “We’re not just exporting solutions – we’re co-creating them with Chinese researchers and institutions.” The first wave of collaborative treatments is expected to roll out by late 2025.
